Flortaucipir F 18 Brand Name– Tauvid
What is Flortaucipir F 18
Flortaucipir F 18 is a parenteral radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
NFTs are 1 of 2 required components of the neuropathological diagnosis of AD; flortaucipir F 18 does not target beta-amyloid neuritic plaque. A positive scan supports the presence of widely distributed tau neuropathology (B3 tau pathology), with increased neocortical activity in posterolateral temporal, occipital, or parietal/precuneus region(s), with or without frontal activity.
The safety and effectiveness of flortaucipir F 18 have not been established in patients being evaluated for chronic traumatic encephalopathy (CTE).
Data suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding.
Therefore, flortaucipir F 18 is not indicated for detection of CTE.
Indications
- positron emission tomography (PET) imaging
For use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease
Side Effects
- headache
- injection site reaction
Of 1,921 patients receiving flortaucipir F 18 in clinical studies, headache (1.4%), injection site reaction (i.e., pain, 1.2%), and increased blood pressure (0.8%) were reported in 0.5% or more of patients.
Monitoring Parameters
- pregnancy testing
Contraindications
- accidental exposure
- breast-feeding
- pregnancy
- pregnancy testing
- radiation exposure
- reproductive risk
Interactions
No information is available regarding drug interactions associated with Flortaucipir F 18
